Human-informed data-driven development of next-generation T cell vaccine against malaria
以人为本的数据驱动开发下一代抗疟疾 T 细胞疫苗
基本信息
- 批准号:10443906
- 负责人:
- 金额:$ 49.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-02 至 2023-01-01
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenovirusesAgonistAntibodiesAntibody ResponseAntigen TargetingAntigensAttenuatedCD8-Positive T-LymphocytesCD8B1 geneCellsCessation of lifeCharacteristicsChemoprophylaxisChloroquineClinicalComplexComputational ScienceDNADataData SetDevelopmentDiseaseErythrocytesGenomeGoalsHumanImmuneImmune responseImmunityImmunizationImmunologyIn complete remissionIndividualInfectionIntravenousLeadLinkLiposomesLiverMalariaMalaria VaccinesMediatingMediator of activation proteinMemoryMessenger RNAMultiomic DataMusNatural ImmunityOutcomeParasitesPhasePlasmodiumPlasmodium falciparumPopulations at RiskPre-Clinical ModelProteinsProteomePublic HealthRNA vaccineRadiationRegimenRiskSelection CriteriaSiteSporozoitesSterilityT cell responseT memory cellT-LymphocyteTargeted ResearchTissuesTranscendVaccinationVaccine AntigenVaccinesVirulentadaptive immunitybaseclinical developmentclinically relevantcombinatorialdata integrationdesignhuman modelimmunogenicityin silicoin vivoinnovationnext generationnovelnovel strategiespathogenpreclinical developmentpreventrational designresearch clinical testingresponsescreeningsynergismtranslational research programtransmission processvaccination strategyvaccine candidatevaccine deliveryvaccine developmentvaccine evaluationvaccine platformvaccinology
项目摘要
PA-19-077 DOOLAN: PROJECT SUMMARY
Malaria remains a global public health problem with nearly half of the world's population at risk. An effective
malaria vaccine would prevent almost half a million deaths and over 200 million clinical cases each year and
help eradicate the disease. The most effective experimental malaria vaccination regimens to date are radiation-
attenuated sporozoites (RAS; PfSPZ) and infectious sporozoites administered under chemoprophylaxis (CPS).
Protective immunity is believed to be mediated by CD8+ T cells which attack the parasite during the pre-
erythrocytic (PE) liver-stage of infection. However, the key antigens underlying this protection are largely
unknown. We have developed and applied a proteome-wide T cell screening approach to identify the subset of
key antigens targeted by T cell responses from the complete Plasmodium falciparum parasite proteome. We
have shown that the antigens preferentially recognized by T cells are distinct from antibody targets. Here, we
will characterize and credential highly ranked pre-erythrocytic P. falciparum T cell antigens from our unique
dataset, focusing on those that are categorized as exclusively T cell targets, since T cells directed against liver-
stage antigens are considered the primary immune effectors required for sterile immunity against malaria which
prevents disease and stops transmission. Our selection criteria will consider extent of sequence conservation
across Plasmodium strains and species, to target a vaccine that confers strain transcending and cross-species
protection. We will use clinically relevant selection criteria governed by the capacity of the antigen to protect
against virulent P. yoelii parasite challenge in established preclinical models and to be recognized by recall
Plasmodium-specific immune responses in protective human models. We will use two innovative vaccine
delivery platforms selected for capacity to induce robust and sustained T cell responses, with a specific focus on
the induction of liver-specific resident memory T cells (Trm) targeting the putative site of immune action. Our
selected regimens include “Prime-Target” comprising a DNA prime followed by adenovirus boost delivered
intravenously to target the liver, and a liposomal mRNA vaccine platform with an incorporated agonist (cA) to
activate NKT cells and link innate and adaptive immunity; both platforms can induce sustained T cell responses
and are capable of protecting mice against sporozoite challenge. We will assign priorities for vaccine
development according to their credentials, evaluate combinations for synergy, and down-select for clinical
development the set of antigens that have a maximum likelihood of inducing robust and sustained protective
immunity against malaria in humans. The optimal vaccine candidate defined with this preclinical development
strategy could be transitioned directly to clinical development with the ultimate goal of deploying in the field an
effective rationally-designed genome-based vaccine that would induce durable T-cell mediated protection and
ameliorate disease in all at-risk individuals.
PA-19-077 DOOLAN:项目总结
疟疾仍然是一个全球性的公共卫生问题,世界上近一半的人口处于危险之中。有效
疟疾疫苗每年可防止近50万人死亡和2亿多临床病例,
帮助根除疾病。迄今为止,最有效的实验性疟疾疫苗接种方案是辐射-
减毒子孢子(RAS; PfSPZ)和在化学预防下施用的感染性子孢子(CPS)。
保护性免疫被认为是由CD 8 + T细胞介导的,所述CD 8 + T细胞在预感染期间攻击寄生虫。
红细胞(PE)肝脏感染阶段。然而,这种保护的关键抗原主要是
未知我们已经开发并应用了一种蛋白质组范围的T细胞筛选方法来鉴定T细胞亚群。
T细胞反应靶向的关键抗原来自完整的恶性疟原虫寄生虫蛋白质组。我们
已经表明,T细胞优先识别的抗原与抗体靶标不同。这里我们
将表征和认证来自我们独特的红细胞前恶性疟原虫T细胞抗原,
数据集,重点是那些被归类为专门的T细胞靶点,因为T细胞直接针对肝脏-
阶段抗原被认为是抗疟疾的无菌免疫所需的主要免疫效应物,
预防疾病并阻止传播。我们的选择标准将考虑序列保守程度
疟原虫菌株和物种,以靶向疫苗,赋予菌株超越和跨物种
保护我们将使用临床相关的选择标准,由抗原的保护能力决定。
在已建立的临床前模型中抗毒性约氏疟原虫攻毒,并通过召回识别
保护性人类模型中的疟原虫特异性免疫应答。我们将使用两种创新疫苗
选择具有诱导稳健和持续T细胞应答能力的递送平台,特别关注
诱导肝脏特异性驻留记忆T细胞(Trm)靶向假定的免疫作用位点。我们
选定的方案包括“初免-靶向”,其包括DNA初免,随后是腺病毒加强递送
静脉注射以靶向肝脏,以及具有掺入的激动剂(cA)的脂质体mRNA疫苗平台,
激活NKT细胞,连接先天免疫和适应性免疫;两种平台都可以诱导持续的T细胞应答
并且能够保护小鼠免受子孢子攻击。我们会优先考虑疫苗
根据他们的资历开发,评估组合的协同作用,并向下选择临床应用。
开发具有最大可能性诱导稳健和持续的保护性免疫应答的抗原集。
人类对疟疾的免疫力。通过该临床前开发确定的最佳候选疫苗
战略可以直接过渡到临床开发,最终目标是在现场部署,
有效的合理设计的基于基因组的疫苗,其将诱导持久的T细胞介导的保护,
改善所有高危人群的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Denise L. Doolan其他文献
The Australasian contribution to malaria vaccine development
澳大利亚对疟疾疫苗开发的贡献
- DOI:
10.1111/j.1365-3024.2010.01229.x - 发表时间:
2010 - 期刊:
- 影响因子:2.2
- 作者:
Andrew M. Redmond;Andrew M. Redmond;Denise L. Doolan - 通讯作者:
Denise L. Doolan
Malaria vaccines–targeting infected hepatocytes
疟疾疫苗——针对感染的肝细胞
- DOI:
10.1038/81315 - 发表时间:
2000-11-01 - 期刊:
- 影响因子:50.000
- 作者:
Stephen L. Hoffman;Denise L. Doolan - 通讯作者:
Denise L. Doolan
Status of malaria vaccine R&D in 2007
疟疾疫苗 R 的现状
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:6.2
- 作者:
Denise L. Doolan;V Ann Stewart - 通讯作者:
V Ann Stewart
Proteomic identification of the contents of small extracellular vesicles from in vivo emPlasmodium yoelii/em infection
- DOI:
10.1016/j.ijpara.2021.06.001 - 发表时间:
2022-01-01 - 期刊:
- 影响因子:3.200
- 作者:
Karina P. De Sousa;Jeremy Potriquet;Jason Mulvenna;Javier Sotillo;Penny L. Groves;Alex Loukas;Simon H. Apte;Denise L. Doolan - 通讯作者:
Denise L. Doolan
Vaxfectin™ enhances immunogenicity and protective efficacy of <em>P</em>. <em>yoelii</em> circumsporozoite DNA vaccines
- DOI:
10.1016/j.vaccine.2005.10.041 - 发表时间:
2006-03-10 - 期刊:
- 影响因子:
- 作者:
Martha Sedegah;William O. Rogers;Arnel Belmonte;Maria Belmonte;Glenna Banania;Noelle Patterson;Marilyn Ferrari;David C. Kaslow;Daniel J. Carucci;Thomas L. Richie;Denise L. Doolan - 通讯作者:
Denise L. Doolan
Denise L. Doolan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Denise L. Doolan', 18)}}的其他基金
Human-informed data-driven development of next-generation T cell vaccine against malaria
以人为本的数据驱动开发下一代抗疟疾 T 细胞疫苗
- 批准号:
10756179 - 财政年份:2022
- 资助金额:
$ 49.59万 - 项目类别:
Proteome-wide cellular immunity approach to P. falciparum antigen identification
用于恶性疟原虫抗原鉴定的蛋白质组细胞免疫方法
- 批准号:
8302969 - 财政年份:2009
- 资助金额:
$ 49.59万 - 项目类别:
Proteome-wide cellular immunity approach to P. falciparum antigen identification
用于恶性疟原虫抗原鉴定的蛋白质组细胞免疫方法
- 批准号:
8131138 - 财政年份:2009
- 资助金额:
$ 49.59万 - 项目类别:
Proteome-wide cellular immunity approach to P. falciparum antigen identification
用于恶性疟原虫抗原鉴定的蛋白质组细胞免疫方法
- 批准号:
7910586 - 财政年份:2009
- 资助金额:
$ 49.59万 - 项目类别:
Proteome-wide cellular immunity approach to P. falciparum antigen identification
用于恶性疟原虫抗原鉴定的蛋白质组细胞免疫方法
- 批准号:
7657552 - 财政年份:2009
- 资助金额:
$ 49.59万 - 项目类别:
相似海外基金
cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
cGAS-STING 通路靶向具有 CD46 趋向性和 AFP 启动子的复制腺病毒条件性复制限制用于治疗肝细胞癌
- 批准号:
10436626 - 财政年份:2021
- 资助金额:
$ 49.59万 - 项目类别:
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
- 批准号:
10557162 - 财政年份:2021
- 资助金额:
$ 49.59万 - 项目类别:
Molecular therapy of replication-competent adenoviruses targeting characteristic gene mutations found in mesothelioma
针对间皮瘤中发现的特征基因突变的具有复制能力的腺病毒的分子疗法
- 批准号:
21K08199 - 财政年份:2021
- 资助金额:
$ 49.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
- 批准号:
10330464 - 财政年份:2021
- 资助金额:
$ 49.59万 - 项目类别:
Structural characterization of nucleoprotein cores of human adenoviruses
人腺病毒核蛋白核心的结构表征
- 批准号:
9807741 - 财政年份:2019
- 资助金额:
$ 49.59万 - 项目类别:
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
- 批准号:
41625-2013 - 财政年份:2018
- 资助金额:
$ 49.59万 - 项目类别:
Discovery Grants Program - Individual
The therapeutic strategies with augmented replications of oncolytic adenoviruses for malignant mesothelioma
溶瘤腺病毒增强复制治疗恶性间皮瘤的治疗策略
- 批准号:
18K15937 - 财政年份:2018
- 资助金额:
$ 49.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
- 批准号:
41625-2013 - 财政年份:2017
- 资助金额:
$ 49.59万 - 项目类别:
Discovery Grants Program - Individual
Research on detection of novel adenoviruses by genetic methods
新型腺病毒的基因检测研究
- 批准号:
16K09118 - 财政年份:2016
- 资助金额:
$ 49.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Exploring the effects of nutrient deprivation on T cells and oncolytic adenoviruses, in order to create immune activators for tumour therapy
探索营养剥夺对 T 细胞和溶瘤腺病毒的影响,以创造用于肿瘤治疗的免疫激活剂
- 批准号:
1813152 - 财政年份:2016
- 资助金额:
$ 49.59万 - 项目类别:
Studentship